InMed Pharmaceuticals Inc. — Director's Dealing 2021

Dec 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: InMed Pharmaceuticals Inc. (INM)
CIK: 0001728328
Period of Report: 2021-12-30

Reporting Person: Johnson Shane Aaron (SVP, GM of BayMedica LLC)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-30	Common Stock	P	8093	$1.3266	Acquired	296095	Direct